| Date | Time | Source | Headline | Symbol | Company |
| 03/08/2023 | 8:30AM | Business Wire | Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer | NASDAQ:ADTX | Aditxt Inc |
| 03/03/2023 | 8:30AM | Business Wire | Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc. | NASDAQ:ADTX | Aditxt Inc |
| 02/24/2023 | 5:11PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 02/14/2023 | 11:17AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ADTX | Aditxt Inc |
| 02/14/2023 | 8:30AM | Business Wire | Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President | NASDAQ:ADTX | Aditxt Inc |
| 01/20/2023 | 4:31PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 01/06/2023 | 4:16PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 01/04/2023 | 8:01AM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ADTX | Aditxt Inc |
| 01/03/2023 | 9:00AM | Business Wire | Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO | NASDAQ:ADTX | Aditxt Inc |
| 12/23/2022 | 4:31PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 12/20/2022 | 9:17AM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:ADTX | Aditxt Inc |
| 12/20/2022 | 9:13AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 12/02/2022 | 4:32PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 11/14/2022 | 4:07PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ADTX | Aditxt Inc |
| 10/21/2022 | 4:22PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:ADTX | Aditxt Inc |
| 10/21/2022 | 9:00AM | Business Wire | Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials | NASDAQ:ADTX | Aditxt Inc |
| 10/12/2022 | 9:00AM | Business Wire | Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection | NASDAQ:ADTX | Aditxt Inc |
| 10/07/2022 | 9:00AM | Business Wire | FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health | NASDAQ:ADTX | Aditxt Inc |
| 10/03/2022 | 4:32PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 09/29/2022 | 9:00AM | Business Wire | Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements | NASDAQ:ADTX | Aditxt Inc |
| 09/27/2022 | 3:35PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ADTX | Aditxt Inc |
| 09/27/2022 | 9:00AM | Business Wire | Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering | NASDAQ:ADTX | Aditxt Inc |
| 09/26/2022 | 6:21AM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ADTX | Aditxt Inc |
| 09/20/2022 | 4:59PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 09/20/2022 | 4:09PM | Business Wire | Aditxt Announces Closing of $20.0 Million Public Offering | NASDAQ:ADTX | Aditxt Inc |
| 09/20/2022 | 9:16AM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) | NASDAQ:ADTX | Aditxt Inc |
| 09/19/2022 | 6:02AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ADTX | Aditxt Inc |
| 09/16/2022 | 9:20AM | Business Wire | Aditxt Announces Pricing of $20.0 Million Public Offering | NASDAQ:ADTX | Aditxt Inc |
| 09/16/2022 | 8:47AM | Edgar (US Regulatory) | Securities Registration Statement (s-1/a) | NASDAQ:ADTX | Aditxt Inc |
| 09/15/2022 | 4:03PM | Edgar (US Regulatory) | Securities Registration Statement (s-1/a) | NASDAQ:ADTX | Aditxt Inc |